CEP-701 for PH-negative Myelofibrosis
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00494585 |
Recruitment Status
:
Completed
First Posted
: June 29, 2007
Results First Posted
: May 4, 2011
Last Update Posted
: June 25, 2012
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Leukemia Myelofibrosis | Drug: CEP-701 | Phase 2 |

Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 27 participants |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Evaluation of CEP-701, an Orally Available JAK2 Tyrosine Kinase Inhibitor, as a Therapy for Patients With Myelofibrosis |
Study Start Date : | June 2007 |
Actual Primary Completion Date : | May 2010 |
Actual Study Completion Date : | May 2010 |

Arm | Intervention/treatment |
---|---|
Experimental: CEP-701
80 mg orally twice a day for 30 days
|
Drug: CEP-701
80 mg orally twice a day for 30 days
Other Name: lestaurtinib
|
- Number of Participants With Objective Response [ Time Frame: Response assessed after each 3 cycles (cycle = 30 days) ]Objective response = Complete Response, absence sign/symptoms of disease (without use of growth factors, hydroxyurea, anagrelide, or transfusions for > 1 month); Partial Response, absence of progressive disease (PD), and improvement in 2+ parameters (if abnormal): Absolute neutrophil count (ANC), hemoglobin, platelets, transfusions, splenomegaly, or bone marrow blasts; Clinical Improvement, absence of PD, and improvement in 1 parameter: ANC, hemoglobin, platelets, transfusions, splenomegaly, or bone marrow blasts). [International Working Group on Myelofibrosis Research and Treatment]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients with Chronic Idiopathic Myelofibrosis (CIMF) requiring therapy, including those 1) previously treated by CIMF-directed therapy and relapsed, intolerant, or refractory to therapy; or 2) if newly diagnosed then with intermediate or high risk according to Lille scoring system (adverse prognostic factors are: Hb < 10 g/dl, WBC < 4 or > 30 x 10^9/L; risk group: 0 = low, 1 = intermediate, 2 = high), or with symptomatic spleen that is >/= 10cm below costal margin. However, patients with asymptomatic intermediate risk disease are not eligible.
- JAK2 mutation positive test
- Age of at least 18 years
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Adequate liver and renal function: total bilirubin </=2.0 mg/dL, alanine aminotransferase (ALT or SGPT) </=2.0 x institutional upper limit of normal (ULN), and creatinine </=2.0 mg/dl
- Patients must be at least 2 weeks from prior chemotherapy, biological therapy, radiation therapy, major surgery, or other investigational anticancer therapy that is considered MF-directed, and have recovered from prior toxicities to Grade 0-1. Concurrent therapy with supportive care medications (hydroxyurea, anagrelide) is allowed during the study.
- All men of reproductive potential and women of child-bearing potential (WOCBP) must agree to practice effective contraception (iud, birth control pill, latex condoms, diaphragm) during the entire study period and for one month after the study ends, unless documentation of infertility exists. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. WOCBP are women who are not menopausal for 12 months or no previous surgical sterilization."
- Ability to understand and willingness to sign the informed consent form
- Not willing to undergo, not a candidate for, or not having a donor for, a bone marrow transplant
Exclusion Criteria:
- Pregnant or nursing women, due to the unknown effects of therapy on the developing fetus or newborn infant.
- Patients diagnosed with another malignancy - unless following curative intent therapy the patient has been disease free for at least 3 years. Patients with early stage squamous cell carcinoma of the skin, basal cell carcinoma of the skin, or cervical intraepithelial neoplasia (CIN) are eligible for this study
- Any condition, including serious medical condition, laboratory abnormality, or psychiatric illness, which places the subject at unacceptable risk as judged by the Principal Investigator, if he/she was to participate in the study
- Known positive for Human immunodeficiency virus (HIV) or infectious hepatitis, type A, B or C
- Presence of any gastrointestinal condition or concomitant medication use (e.g. coumadin) that would render a patient at high risk for gastrointestinal bleeding as judged by treating physician
- History of any upper or lower gastrointestinal bleeding in the 6 months prior to enrollment
- Elevated international normalized ratio (INR) or Partial thromboplastin time (PTT)

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00494585
United States, Texas | |
The University of Texas M.D. Anderson Cancer Center | |
Houston, Texas, United States, 77030 |
Principal Investigator: | Srdan Verstovsek, M.D. | M.D. Anderson Cancer Center |
Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | M.D. Anderson Cancer Center |
ClinicalTrials.gov Identifier: | NCT00494585 History of Changes |
Other Study ID Numbers: |
2007-0070 CS-2007-20040 |
First Posted: | June 29, 2007 Key Record Dates |
Results First Posted: | May 4, 2011 |
Last Update Posted: | June 25, 2012 |
Last Verified: | June 2012 |
Keywords provided by M.D. Anderson Cancer Center:
CEP-701 Leukemia Myelofibrosis MF JAK2 |
Tyrosine Kinase Inhibitor Lestaurtinib Chronic Idiopathic Myelofibrosis CIMF |
Additional relevant MeSH terms:
Primary Myelofibrosis Myeloproliferative Disorders Bone Marrow Diseases Hematologic Diseases |